FOSIINPHARMA

上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

 $(\ \, \ldots \ \, , \ \, \ldots \ \, , \ \, \ldots \ \, , \ \, P \ \, , \ \, , \ \, \ldots \ \, , \ \, C \ \, \ldots \ \, , \ \, \ldots)$ (Stock Code: 02196)

2014 FIRST QUARTERLY REPORT

	m · · · · · · · · · · · · · · · · · · ·	m , ,	Δ1 (I	1 .0 (2)	, f (_{1 ,} 1 ,	1 .10	#
1.* ("Company	Λ Λ. ", !	A A , A	b 1 r ,		"Group").	(A1,) A, A

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu

 C_1 ,

2 A, r 201.

* F , . . . , . , . , . , . , . , . , . .

1 IMPORTANT NOTICE

2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDINGS OF THE COMPANY

- . . I . _ I M. . . . ()

			Change recorded at the
			end of the Reporting
			Period compared with
	As at the end of the	As at the end of the	the end of the previous
	Reporting Period	previous year	year (%)
(1)	0,0,2,2,1,1,.2	2, , 1, 0, , 1., 1, 2,1,.,, .0	1, .
. x'_1 . (x x . 1 x'_1 x'_1 .) (1)	£, 2, ,,1.,.£	£, 2,1,.,., .0	1,
, ,	, , ,	From the beginning	
	From the beginning	of the previous year to	
	of the year to the end	the end of the Reporting	
	of the Reporting Period	Period of the previous	Year-on-year change
	(Jan – Mar)	year (Jan – Mar)	(%)
(N-)	,02, 1,	,1,1,,11,	-, O.
	From the beginning	From the beginning	Year-on-year change
	of the year to the end	of the previous year to	(%)
	of the Reporting Period	the end of the Reporting	(70)
	(Jan – Mar)	Period of the previous	
	(Jan – Mai)	year (Jan – Mar)	
, # # (1)	2, 1, 2, 1,	2,0 1.2.	2 .2.
$[, x_{-1}, $.2(. ()(.)- ,)	, ,	

	Current Amount	
Items	(Jan – Mar)	Description
	, 0 [] . ,] 0 _y .	1 ., h
Am. 16 1 11 1 1 1 1 1 1 A A A B A B A B A	., 1,000.00	
b, A, A, A, B, M, A,	11. , . 0, 1 .21	1 .
. A, A	-1 , ₹ ,0.2. _/	
••• • • • • • • • • • • • • • • • • •	, ., 01	
m, m. f f. (, f. /)	∮ , 02,0. 1	
	110, , . ,	

2.2 $\frac{1}{1}$ $\frac{1}{1}$

_ : r

······mb #. # # #					, . ,2, 0	
The shareholding status of the Top 10 shareholders						
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen	
	m,	. 1.02	, 20, . 1, 1.	0	1	
1 1 1 1 - 1 -	Æ i	1	1 , 1 , 0	0	<u></u>	
1 , , 10 , . A. ,		1.22	2.,, 2	0	1	
		0 _γ .	1, 2, 1, , ,	0	1	
# # / mm # = - - - - - - - - -		0, 0	1, ,000,000	0	1	
1 ,		0	1., , , ,22.	0	1	
Colonia bi - , IA		0	1., 02,.0	0	1	
1		0.2.	12 , 1.	0	1	
* mim * A		0.1	11, ,	0	1	
, sp , st. , m		0\$	10,1, 2, . 0	0	1	

The shareholding status of the Top 10 unrestricted shareholders of tradable shares				
	Number of unrestricted tradable shares held at the			
Name of the shareholder (in full)	end of the reporting period	Type and number of shares		
	, 20, . 1, 1.	(
(N)	£,£, 0	x , 1 , x , x		
1	2.,.,,,	(', A, x x		
	1,21,	() , A ¹ , A A		
$\frac{1}{\sqrt{1-1}} \frac{1}{\sqrt{1-1}} 1$	1, ,000,000	(1 , A ¹ , a a a		
1 ,	1. , , ,22.	() A ^d , Ac Ac		
(b , - 14	1., 02,, 0	() A, A, A, A		
A A A Mark A Mar	12 , 1.	A A BA ID		
······································	11, ,	(
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	10,1, 2, . 0	(1 , 1) A		
л, л, Лл, , .л д b л л	mm' — I A A A A A A A A A A A A A A A A A A	m '		

 $N: (-1) \mid (-1)$

3 SIGNIFICANT EVENTS

- . . I . _ I M. . . . ()

	Balance Sheet					
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons		
, A-, A _m .	2,0., ,, ,121.20	1, , 00, 2 .	., %	1 . A		
A _{m./}	2, , 2, , 1, 2	12 , 1, ,1. 1, 2	1. 1%			
		Income State	ement	,		
		Amount of				
	Current Amount	the last period	Ratio of			
Items	(Jan – Mar 2014)	(Jan - Mar 2013)	change	Reasons		
, A	1111,0.,	1,1. 21, , 0 1	. %	л , д 1		
Af m	. 1, 2, ,2 . , 2	2 . ,0, . ,110.1.	§ . %	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		
	1 ,0 1.	2, 1, . 2, .	- 5. %	Alitant, al		
("—" . 1	. 01, 1. , . , 2	2 1,200,01 .1.	%	1		
! . . , . & ,	, , , , 0. d	1, 0, 0,	5 . %	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		
· · m • / /, ·	. 2,11, ,	. 0, 0. , 0	1. %	π		
, , , , , , , , , , , m	,10,,.21	1 , . ,	- 1. 2%	1 1 1 , , , , , , , , , , , , , , , , ,		

() $\frac{2}{1}$ $\frac{1}{1}$ \frac

4 APPENDICES

Consolidated Balance Sheet

31 M 2014

*, * b . Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
- · / b · · b · ·	,02 ,, 0 ,0,	,0.,1,
and the state of t	,	
b		
1 . A . A . A . A . A . A . A . A . A .	,1, , 0	,1,1,1
b	1, 1, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	1.,1.,1 ¹ 11 _y ,
, A B	1,2,020, 2,	1,2 , , , 1 , , 202, 00, ,
, , , , , , , , , , , , , , , , , , ,	2,10 ,.0.,	202, 00, 2.
1 m m 1 b		
(, , , , , , , , , , , , , , , , , , ,		
(, , t , , , , t , t , b		
1 1 t p	1,,0 1,,d,. 2,,d	22, .20
	II., I., , , , , , , , , , , , , , , , ,	F. ,1., ,U , ,
, κ.κ. β.	2,, U.L	/ · · · · · · · · · · · · · · · · · · ·
	1, , , , 1, , , 1	1, 1, ,2, 1, , , , , 0
11 AC	1, , , 1	1, 1, ,2, 1, ,4 . 0
A LAK.	0., 02	. ,2. 2,1 , .12
I AA	,20, ,1, ,1, .02	. ,2. 2,1 , .12
Non-current assets:	. ,20, ,4, ,9, 14, ,02	· , , · 4. , · , · 0 ₁ . \(\)
A A I		
A b - A-	1	1, . 2, . , . , . , 2
Ar i i i i i i i i i i i i i i i i i i i	19.77, 17, 1, 2, 2, 1,	1, 2, 1, 1
7 m J A m		
1 - 1 - 1 - m	10,212, 2, 2, 2	., 2,0 ,20 ,1.
m , , , , , ,	- 7 7 7	7,4 1,7 1
, / 1 ^m ,	53,5,6	£, 2,£, , . 0, .
, ,	1, 1, 1, 12.1,	1, 21,0 0, 2 . 1
, A	.,2 11	. ,2 1, . , .2
		i
Att. bast		
b		
·		

Consolidated Balance Sheet (Continued)

31 M 2014

		,
2,0. AT I A T I A T I A T I I I I I I I I I I	, 20, , 0, 1	,
AR I R	, 20, , 0, 1	,
## ## ## ## ## ## ## ## ## ## ## ## ##	, 20, , 0, 1	,
1 1,1 1,1 200	, 20, , 0, 1	
1 1,12 1,12 200	, 20, , 0, 1	
1 1,1 1,1 200	, 20, , 0, 1	1 5 5
1 1,12 1,12 200	20, 0. 1	1 4 4 4 4 4
200	2.21	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
	, , 2,2 p. , ,	2 , 22,211
$f_{ij} = f_{ij} = f$	0,2, 0, 2	2 ,. 22,21 1
$\overline{7}$, $\overline{6}$,,1,1	2. ,0. , 2, .2,
$\frac{2}{2}$	2,1,1,2, 0,11,1,1,1,1,1,2,1,1,2,1,1,1,1,1,1,1,1,1	2, , 0, ,2, , , , , , , , , , , , , , ,
	0, 11, 1.	1. , 22 , ,2
1 1 1 b	1,2.,	1, 12,02, 1.
1,21.	, 1, ,2, , .1,	1, 12,02. , 1. 1
(, 1 £ , 1 , , , , b,		
Am 1. , f A 1. 1 A A A 1. 1 A 1. 1 A A 1. 1		
A _m , 1, s, T, A, 1, s, 1A, 1, T, A, A, 1	0 0 0 00	0 0 0 0 0
1, -1, A, b, 71 A	0, 0, 0, 0.00	. 0, 0, 0, 000
A.	,100,1. 1, 21,	1, 10,02 .11 2, 2, ,121,21
Non-current liabilities:	1, 21,4	1. ,2. , 121,2 1
	2 1 2	12 1 1 1 2
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	, 2, , 1, 2 , 2, , 1, 1, 1 1, 2, 22, 2	12 , 1, 1, 1, 2
	1 2 22 2	. 0. , , , ,
m, b	1, 2, 224. 2	, 0, ,, , , , ,
A A D		
12 (0,0,,1.	1. 11
, r i / r b	022 .	1
, 2	0, , , , , , , , , , , , , , , , , , ,	2 2 0.
12,1.	0, 2	11, 10,, 0
Equity attributable to the owners (or equity attributable to shareholders):	 1	7 ., ,,
	, , , ,00	2,2, 0, . 2,00
	, 21, 1, .2	. 101,, 12.2
, , K 1 K K		
_ ,		
	, , ,1, , ,	1,, 1, ,1,
, A, A, , A		,
	, 12, . 0. 0	,112, , 2, 2, .1,
-2	2,2 ,0. 0. 1	-,0,,, 1, 2,1,, .0 2, 2, 2,1
1, 2,	,,,,, <u>,</u> 1,,, 1	1, 2,1, .0
2,2	, , , , 1, , , 1, , , 1, , , , , , , ,	2, 2, 2,1
	2, 10. 1	1.,, 1.,1
	2,2.1 1	2 , 1 ,1 0, . 1.



Balance Sheet of the Company

31 M 2014

, *, * * b . Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

I I AT ()	, d	, , d d
	~ · · · · · · · · · · · · · · · · · · ·	

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
- · / b · · b , ·	, 1 ,0 🖡 , 0 . 0	, 2, ,1 1, , 1
A A A A A A A A A A A A A A A A A A A		
. x ∮ x b		
, , , , , , , , , , , , , , , , , , ,		
т . р	,,121, 0. 🐔	2. 11. , 11. 10
1 1 x b	1. , \$. , 22 , .	1. , 5. ,22. , .
· ' ' ' ' P'	1, 0,02, 15.1.	1,,, .21 .0.
, , , , , , , , , , , , , , , , , , ,	1, 0,02, \$11.1. £ 1.,	1,,, .21 .0.
11 AC		
, K + KK	,000,000.00	2. ,000,000.00
1 KT	, . , . 0, 2 . 1	,0, 2,0 1, ,22,
Non-current assets:		
A , h - , t- ,		
A b - x-		
x b		
! ¹ m -! - · · · · · · · · · · · · · · · · ·	1,2,1,.10	£, , 0, . £ £ . 2
		1 1
, 1	1,,2.1	20,1. ,0,
	1,7,7	
K		
, , , , , d		
K. 11		
1		
	2, 0, 11,	,6, ,0 , 1 2
promise / p. of a st	2, 6, 11,	,9.5,0 ,4.2
, m		
il-in and in the		
AT 1 m		
. A	, 1 1, , , 1 1	0. 22. 2 0
I AT.	.,	.,0.2,,2,2,0
	1 ,1 . ,2 . ,0	12, 2,1, 0

Balance Sheet of the Company (Continued)

31 M 2014

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:	or the Terrou	or the real
~ . K K _{m+}	, 10,000,000.00	. 0,000,000.00
1 . x . x 1 . i	,	
, b		
, , , , b,		
(),		
/ r , · b _i	1,1,0,0,0	. 0 ₇ 2 , 11
- / , / b _i		22,22,,
л., в,	10, ,2, 2, ,, , 0	1,1.11
	5	5
л, b,	,1.,	, 12, 2
т т мг, в, л	. 0,000,000.00	. 0,000,000.00
, A + AA	1,0, 1, 1,2	2 02 6 1 6
Non august liabilities	1,0 . , 16 , 16 . 2	. 2. ,02. ,01. 1.01.
Non-current liabilities:	2 ,000,000.00	12,000,000.00
d b	.,05, 2, .1.	. ,0. , . 1,2. 0 ,
	,,0.4., 2.,, 1.	,,0. ,, 1,2. 0,
A M d b.		
мг. ј		
, rı xr, b, .	1, \$,000.00	2,6 0,000.00
	. , 02, 02, 1.	. ,200, . 1,2. 0. ,
	5, , , , 1, 5, 5, 5	. , 2, , , 2, 1.
Equity attributable to the owners (or equity attributable to shareholders):		
<u>ф</u> -,,(к к ,,)	2,2,	2,2, 0, . 2,00
, , A A	,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,,	, , , , , 1,2 , 1
, , f f f		
, A A		
_ K, K K	.£.,, 0,1 £.	.£., 0,1 £.
	1,6, , 22, 11,	1,6, 1,0, 1, 2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$, 1, 1, 1, 1, 0	., 1,, 1,
- x 1 x y x y	1 ,1 . ,2 . ,0	12,55, 2,10

Consolidated Income Statement

J - M = 2014

x, $x \not \mid b$. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

 r , ()	, , , , , , , ,	1 d	, d
	,		

Items	Current Amount	Amount of the Last Period
, # 1 # 1	2, 1, 2, 1, ., .	2,0 . 1,1 . , 1.2
	2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2	2,0 . 1,1.2
	/ /	/ /
τ /, τ _m ' _m		
mmm		
, , , , , , , , , , , , , , , , ,	2, 20, . , 0, 1	1, 2, , , , 11, ,
. it. i. , f. i	1,22 ,0.,	1,1, 2, , 0, 1
, mm /,		
, r m m , r 1 , 1		
- · · · · · · · · · · · · · · · · · · ·		
Ι , κ		
1 1 1 m · m · m		
A _m A A A A A A A A A A		
1 / . 1 I A A	1.,, 2.2	$\frac{1}{5}$, $\frac{02}{7}$, $\frac{2.1}{5.5}$
A!	1, 2, 1,211.12 1, 2, 2, 2 2, 11,	. 0. , 02,
Af mf /, .	1, 2, 2, 2	2 ,0, . ,110.1.
<u></u>	. 2, 1,	, , , , , , 210, .
A m fm	1,220, 12. 0 1, 2, 0 1.	210,
, , , , , , , , , , , , , , , , , , ,	17.2,0.1.	2, 1, . 2, .
("-" ·! · · · ·)	. 01, 1.,.,. 2	2,200,01 .1.
A m Am	2,, 0,, 2.	1 ,,1
	· · · · · · · · · · · · · · · · · · ·	, , , , , , , , , , , , , , , , , , ,
	1. 0 _y ,0. 2.	, 01,1.
1 1 1, A . 1 A . 1	, , , , 00.	1.,00,
11 → , A 1 / , .	1.0 _y ,0.2 , 0.0.0 , 12 _y 0	, 2, , d , .
. 19.11	, , 1	. 12 0.0
**************************************	1 1 1 000 2	. 2, 0, 1,
	. 2,11 ,	. 0, 0. , 0
/ · · · · · · · · · · · · · · · · · · ·	., 2,, 0,	. 12,
1 , A , A B , B , A , A ,	2,11 ,	4. 2,00. ,2 1
. /	.,.0,.,1	. 0, . 0, . 1
(. K . 1 , K . K ,		
$(1)_{b}$ \mathcal{L} , \mathcal{L}	0.1,	0.1.
(2) 1 1 A 1 A A	0.1,	0.1.
, , , , , , , , , , , , , , , , , , ,	,10,,21	2
' m	. 1, , 0, 2.	, 1.20
	11, 1, 1, 1,	0, ,0,2
\mathbf{m}	2	i , d. i 0 i

Income Statement of the Company

J - M = 2014

x, x∮b. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

 1 1 AX ()	d	, d d
 	- ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	

Items	Current Amount	Amount of the Last Period
. , 1 . 1	Current Amount	Eust Terrou
, K., I.,		
1 A 1. A . A		
A ¹ _m	2, 10, 1	20, 2.,00 .02
· · · · · · · · · · · · · · · · · · ·	- ,1., ,20, 1	,20.,2
A . m. /m		·
1 . A		
("-" . 1	2, ,10, ,22,	2.,,1,,1,,1.,
if it is a man in the state of	2, 0, 2,	2.,,1,,1
. , # . , # . ("-" .)	-1,02 ,	2. 1, 10,
1 / L, K. I K . I	5,000.00	. ,0 2. ,
11, A /, .	2. 0,000.00	∮ ,11 2
, A . ("-")	-1,20, ,	2. 5, ,202
, Æ . ("-" . Å)	-1,20, ,	2.5,,202
, K., K.		·
(1) b 4 1 , 4 4	-0.00	0.12
(2) 1 1 A A A	-0.00	0.12
/		5 .,20
Land to the second seco	-1,20, , ,	2.1, 0, 11.2

Consolidated Statements of Cash Flows

J = -M = 2014

*, * * b . Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I. Cash flow generated from operating activities:		
т 1 д _т	,0 1, 22,, 1,	2, ,, ,0.
l . A b AA I A . A b .		
1 A A		
_ / / / / / / / / / / / / / / / / / / /		
1		
1		
l adaia idi		
(1.1	1, , of , , 0	. ,2 . , . ,.
A A A A , A	1, y of ,, 0 . 0,, 2 ,12,,,	.,,.,.0.,
Thomas American	,12, , , ,	25 , , , , , , , , , , , , , , , , ,
	1, 11, 1 ,	1, 6, , , , , , , , , , , , , , , , , ,
1 t	/	
1 #		
1		
, 1 . t . , . , . , . , . , . , . , . , . ,		
- , t . t . b must	, 20,2,0	1, 22,
	2, 01.	2. , 2 ,22
A , A A , . 1 , A	., 1, , . , 1,	2. , 2 ,22 1. , 1. 0
orbon, and Am, Ant	,11, ,, . ,	2, 01, 1,
1 . I I I	,02, 1,	. ,1.1 , . 11,
II. Cash flow generated from investing activities:		
	1.,,,1,10	1, 0.10
_ / / / / / / / / / / / / / / / / / / /	, £ 0, 0. y £	1, 0.10
_	·	2,0.5 5 22.22
· · · · · · · · · · · · · · · · · · ·	, 1, ½, , , , , , , , , , , , , , , , ,	2,0.4. 4. 22.22
1. A 1 A 1 A 1	0,10,000.00	0,000,00
· · · · · · · · · · · · · · · · · · ·	2. \$.\$.,1.1.	1, 0,000.00
1 b A m 1	2 j. , i. , l. 1,	
, f . t	5 5 0	22. , 1,2 .21
- , ! , #	. 1, 1, , , 2, ,	1,2, 0,000.00
	1 10 0	1 1 2
l , f . a . l . l . l . f . a . , a . l . l	. 1. , 10, , 0	1, 1, 1, 2
A , 1 A , . 1	1,2 1,1 .2	1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1	//·, 1. 55 , 1	2, , , , , 21.1
I . I . I . I . I	-, ,, 1, ,, 2,	- , .,0

Consolidated Statements of Cash Flows (Continued)

 $J = \lambda - M = 2014$

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
т 4 л _т ,	.£.,1, 0.00	
It is a think a am a man	,1, 0.00	
_ x / x _{mb} ,xx .1	. 1 2 1 1 . 1	1, ,0, , 02.00
_ x		, ,
A A A A A	21	
Δ 1 b	., 2,20 , 20,	1, 0, , 02.00
- , 1 A b m -	12, 2, ,2, ,	1, , , 0, 1
, 1 . x . 1 . x	20. ,22. , , ,	1,2.1., 00
ital tit it, a., to obta	, 0,000,000.00	1,, 2, 0
, A , A ,	1, ., , . 1, .	, ,2 , ,0, , , 2
-16	0,5., 010	5 2, . , 2
I A A A A A A A A A A A A A A A A A A A	. 1, . , 1.,,	-1, 0 ,
IV. Effects of exchange rate fluctuations on cash and cash equivalents	,,,00	-, 0, ,, ,, ,,
V. Net increase of cash and cash equivalents	,000,201.,	- !! , 2,1 , .2
μ, , , , , , , , , , , , , , , , , , ,	2, 1, 2, 0, , .2	. ,1. 1 , . 2.12
VI. Closing balance of cash and cash equivalents	2, 5 ,2 0 1.0	1 1 1 2 , 0 , .

Statements of Cash Flows of the Company

J - M = 2014

r, r, b, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Current Amount	Amount of the Last Period
I. Cash flow generated from operating activities:		
a familia fatali a		
. к 1 к _{т.} . г. 1 . 1 к. 1 к. г. к Ст. 1 1		
. л. л. Дл., л., л.,	, § ,, 2.12	f , , , , 10
Am, A.I.	, 1, 2.12 , 1, 2.12	£,,,,10
	, ,	
, 1 1	2 , 1 ,2, .1	21, 2.
	2 , 1 , 2, , 1 f f f , 10, 2	, ,2 ,
. A , A A , . 1	,,00, , . 0	21, 2. ,2 . ,
the American		
1 . K.I.K., K.I	, , , , , , , , , , , , , , , , , , ,	-2,02,2 5
II. Cash flow generated from investing activities:		
	200, 0	1.1,, 1
	/	

Statements of Cash Flows of the Company (Continued)

 $J \sim -M \sim 2014$

Items	Current Amount	Amount of the Last Period
III. Cash flow generated from financing activities:		
т 1 л _т , л _б		
_ x / x _ b . xx 1	5 0,000,000.00	
_ x / x _ r.r.b./		
A A A A	1, . , . , 1	£.,£.,.1.0
∠16	2, 2, , , , , 1	£.,£.,.1.0
, 1 x1 b m	, ,	
, 1 x 1 xb 1 1 1 1, x . x . x .,	10.,1, 11 11	10. \$ 00,000.00
. A , 1 A	1, 1, 2, , ,	, 02, ,0 2
216	1, 5, , , 2, , 1, .	, 0, ,1, ,0, , 2
1	., 1, 1, 1,	-2, ,211, 0, .22
IV. Effects of exchange rate fluctuations on cash and cash equivalents	.,12 , 1	4 1 . 2 . 1
V. Net increase of cash and cash equivalents	-1 ,11, 1 , 2.11	₹ , 2,1, , 2
, b	1,22,1	2,0,0,1,0,
VI. Closing balance of cash and cash equivalents	£ 0.,1£,0.0	1,,,,,,1, 1, 1, 0

1 , A	- , ,	Æ,	r , r, , A , i , , , i
- · m' · · /- · · · · · · ·	r , $ar{f i}$ $=$ $ar{I}$		$r_{\rm m}$